Hanada Shoji, Nishiyama Noritoshi, Mizuguchi Shinjiro, Yamano Shotaro, Kakehashi Anna, Wei Min, Inoue Hidetoshi, Komatsu Hiroaki, Chung Kyukwang, Suehiro Shigefumi, Wanibuchi Hideki
Department of Cardiovascular Surgery, Osaka City University, Graduate School of Medicine, Japan.
Osaka City Med J. 2013 Jun;59(1):35-44.
To identify a useful biomarker for human lung squamous cell carcinoma (SCC), the expression of cytokeratin19 (CK19) in human SCC tissue was investigated. In addition, we examined the significance of CK19 expression levels by immunostaining and CYFRA21-1 levels in preoperative serum, and their correlation with the clinicopathologic features of human lung SCC.
To identify proteins in cancerous and non-cancerous tissues for the diagnosis and prognosis of SCC, QSTAR Elite LC-MS/MS was used. Immunostaining for CK19 was classified as either "CK19-strong" or "CK19-weak". Correlations between prognosis and both CK19 expression in tumor tissues and serum concentrations of CYFRA 21-1 were analyzed in 107 cases of lung SCC.
The upregulation of CK19 in human squamous cell carcinoma tissues was observed by LCMS/MS. The weak expression of CK19, as determined by immunostaining intensity, was a significant predictor of poorer disease-specific survival (p = 0.032). The prognosis was significantly poorer for patients with weak CK19 immunostaining in tumor tissues and a high serum concentration of CYFRA21-1 compared with the other groups (p = 0.003).
The combination of weak CK19 expression and high serum CYFRA21-1 levels is a predictor of poorer prognosis for patients with human lung SCC.
为了确定一种对人肺鳞状细胞癌（SCC）有用的生物标志物，研究了细胞角蛋白19（CK19）在人SCC组织中的表达。此外，我们通过免疫染色检测了CK19表达水平的意义以及术前血清中CYFRA21-1水平，并研究了它们与人肺SCC临床病理特征的相关性。
为了鉴定癌组织和非癌组织中的蛋白质以用于SCC的诊断和预后评估，使用了QSTAR Elite LC-MS/MS。CK19免疫染色分为“CK19强阳性”或“CK19弱阳性”。对107例肺SCC患者分析了肿瘤组织中CK19表达及CYFRA 21-1血清浓度与预后的相关性。
通过LCMS/MS观察到人类鳞状细胞癌组织中CK19上调。根据免疫染色强度确定的CK19弱表达是疾病特异性生存率较差的显著预测指标（p = 0.032）。与其他组相比，肿瘤组织中CK19免疫染色弱且血清CYFRA21-1浓度高的患者预后明显较差（p = 0.003）。
CK19弱表达与血清CYFRA21-1水平高的组合是预测人肺SCC患者预后较差的指标。
